Home » Topics » Regulatory » EMA

EMA
RSS

EMA validates Clovis' application for Rubraca as maintenance treatment for recurrent ovarian cancer

July 6, 2018

Detection of NDMA in Zhejiang Huahai's valsartan leads to EMA review and product recall

July 6, 2018

EMA committee recommends marketing authorization for Veyvondi

July 2, 2018

CHMP adopts positive opinion for Yescarta

July 2, 2018

Kymriah granted positive CHMP opinion for the treatment of two aggressive blood cancers

July 2, 2018

Vyxeos receives positive CHMP opinion

July 2, 2018

EMA committee recommends approval of Cablivi for aTTP

June 29, 2018

CHMP adopts positive trend vote recommending the approval of the MAA for neratinib

June 27, 2018

EMA validates Giapreza MAA

June 26, 2018

EMA grants PRIME designation for Themis' Chikungunya vaccine

June 12, 2018

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...